Aktionärsstruktur

Inhaber in %
Freefloat 99,09
Baker Bros. Advisors LP 14,85
Baker Bros. Advisors LP 14,72
T. Rowe Price Associates, Inc. (Investment Management) 13,59
T. Rowe Price Associates, Inc. (Investment Management) 10,80
Vanguard Group, Inc. (Subfiler) 9,13
The Vanguard Group, Inc. 8,70
Wellington Management Co. LLP 6,24
Wellington Management Co. LLP 6,19
Vanguard Health Care Fund 4,82
Capital Research & Management Co. (International Investors) 4,14
State Street Corp. 3,90
BlackRock Fund Advisors 3,68
Renaissance Technologies LLC 2,89
Vanguard Total Stock Market Index Fund 2,39

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2015 2016 2017 2018 2019
Personal am Ende des Jahres 692 980 1.208 1.367 1.456
Umsatz pro Mitarbeiter in Mio. EUR 1,09 1,13 1,27 1,38 1,48

Bilanz (in Mio. EUR) - Aktiva

2015 2016 2017 2018 2019
Summe Umlaufvermögen 842 994 1.505 1.832 2.481
Summe Anlagevermögen 791 1.071 1.655 1.943 2.670
Summe Aktiva 1.007 1.639 2.303 2.646 3.427

Bilanz (in Mio. EUR) - Passiva

2015 2016 2017 2018 2019
Gesamtverschuldung/ -verbindlichkeiten 620 651 24 17 72
Summe Fremdkapital 836 1.219 672 720 828
Summe Eigenkapital 171 419 1.631 1.926 2.598
Summe Passiva 1.007 1.639 2.303 2.646 3.427

Adresse

1801 Augustine Cut-Off, 19803 Wilmington
Telefon +1 (302) 498-6700
Internet http://www.incyte.com

Management

Barry P. Flannelly
Executive Vice President & General Manager
Christiana Stamoulis
Chief Financial Officer & Executive Vice President
Dashyant Dhanak
Chief Scientific Officer & Executive VP
Edmund P. Harrigan
Independent Director
Hervé Hoppenot
Chairman, President & Chief Executive Officer
Holly Koblish
Associate Director
Jacqualyn A. Fouse
Independent Director
Jean-Jacques Bienaimé
Independent Director
Julian Charles Baker
Lead Independent Director
Katherine A. High
Non-Executive Director
Keith Mikkelson
Executive Director-Business Development
Kim Solomon
Vice President-Project Management
Lothar H. Finke
Head-Clinical Development & General Manager-Japan
Maria E. Pasquale
Secretary, Executive VP & General Counsel
Michael Charles A. Booth
Vice President-Investor Relations
Michael Morrissey
Executive VP & Head-Global Technical Operations
Paul A. Friedman
Independent Director
Paul J. Clancy
Independent Director
Paul Trower
Vice President-Finance
Paula J. Swain
Executive Vice President-Human Resources
Peter Langmuir
Vice President-Oncology Drug Development
Phillip Liu
Associate Director-Applied Technology
Robert Newton
Vice President-Drug Discovery Biology
Steven H. Stein
Chief Medical Officer & Executive Vice President
Vijay Iyengar
EVP-Global Strategy & Corporate Development
Wendy L. Dixon
Independent Director
Wenqing Yao
Executive Vice President-Discovery Chemistry